Rolf Issels (born 25 April 1948 in Mönchengladbach, Germany) is a medical oncologist and biochemist. He performed the first regional hyperthermia in combination with chemotherapy in 1986.[1]
Education and career
editIssels studied human medicine at the Ludwig Maximilian University of Munich and biochemistry at the Karl Eberhard University in Tübingen. He received his doctorate degree in human medicine in 1977. In 1980, he received his diploma in biochemistry.[2]
In 1978, he began working as a research assistant at the Medical Clinic III at the Großhadern Clinic of the Ludwig Maximilian University in Munich, with a focus on haematology and oncology.[2]
With a scholarship from the German Cancer Aid (1982–83), Issels began experimental studies on sarcoma cells and heat shock as a Research Fellow of the Harvard Medical School. He worked at the Massachusetts General Hospital in Boston.[2]
In 1990, Issels became a senior physician at the LMU's Medical Clinic III.[2] In 1996, he was appointed professor.[3] In 2010, he took over as head of the newly founded Sarcoma Center (SarKUM) at the LMU.[2]
Achievements
editOn July 10, 1986, Issels performed the world's first regional hyperthermia with systemic chemotherapy without complications on a 36-year-old female patient with extensive pelvic sarcoma at the Großhadern Hospital.[4][5] From July 1986 to July 1989, a tumour response rate of 37% was achieved in a phase II study in a total of 40 therapy-resistant sarcoma patients, whereby the temperature measured in the tumour significantly distinguished the responders from the non-responders. For the publication of these results in the Journal of Clinical Oncology, Issels was awarded the annual German Cancer Prize of the German Cancer Society in 1991.[6]
The subsequent randomised, multicentre phase III EORTC-ESHO 95 study in Europe of 341 high-risk soft tissue sarcomas showed a significant survival benefit for patients who received a combination of regional hyperthermia with chemotherapy before and after surgery.[7][8] The results led to the inclusion of regional hyperthermia in the treatment guidelines for sarcomas and to reimbursement of treatment costs by health insurance companies.[9] The analyses of the immune infiltrates in the patients showed a significant increase in tumour-infiltrating immune cells with simultaneous suppression of immunosuppressive factors.[10]
In addition to his clinical research, Issels has been involved in biochemical studies on the induction of heat shock proteins since 1982 and, since 1992, in the immunological significance of stress proteins for the immune response against cancer in a research group funded by the German Research Foundation (DFG).[11][12]
In 2018, Issels was appointed Senior Consultant by Michael von Bergwelt, Head of the Department of Internal Medicine III.[13]
Awards
edit- 1991: German Cancer Award of the German Cancer Society[14]
- 2003: ESHO Award (European Society for Hyperthermic Oncology)[2]
- 2010: Science Award of the Working Group of Internal Oncology for the clinical part[15]
- 2014: J. Eugene Robinson Award of the American Society for Thermal Medicine (STM)[16]
- 2019: Elected as a member of the Cell Stress Society International (CSSI)[17]
- 2021: George M. Hahn Award of the American Society for Thermal Medicine (STM)[18]
References
edit- ^ "HelmholtzZentrum münchen Annual Report 2010" (PDF). 2010. Retrieved 17 December 2023.
- ^ a b c d e f "Curriculum Vitae Prof. Dr. med. Dipl. Biochem. Rolf D. Issels". Atzelsberger Kreis für Klinische Hyperthermie. 17 May 2013. Retrieved 17 December 2023.
- ^ "Informationsdienst / Pressereferat der Ludwig-Maximilians-Universität München 1996" (PDF).
- ^ Issels, R. D.; Wadepohl, M.; Tiling, K.; Müller, M.; Sauer, H.; Wilmanns, W. (1988). "Regional Hyperthermia Combined with Systemic Chemotherapy in Advanced Abdominal and Pelvic Tumors: First Results of a Pilot Study Employing an Annular Phased Array Applicator". Application of Hyperthermia in the Treatment of Cancer. Recent Results in Cancer Research. Vol. 107. pp. 236–243. doi:10.1007/978-3-642-83260-4_35. ISBN 978-3-642-83262-8. ISSN 0080-0015. PMID 3375557.
{{cite book}}:|journal=ignored (help) - ^ "LMU Clinical, Fact Sheet Clinical english" (PDF).
- ^ Issels, R. D.; Prenninger, S. W.; Nagele, A.; Boehm, E.; Sauer, H.; Jauch, K. W.; Denecke, H.; Berger, H.; Peter, K.; Wilmanns, W. (November 1990). "Ifosfamide plus etoposide combined with regional hyperthermia in patients with locally advanced sarcomas: a phase II study". Journal of Clinical Oncology. 8 (11): 1818–1829. doi:10.1200/JCO.1990.8.11.1818. ISSN 0732-183X. PMID 2121910.
- ^ Issels, Rolf D.; Lindner, Lars H.; Verweij, Jaap; Wust, Peter; Reichardt, Peter; Schem, Baard-Christian; Abdel-Rahman, Sultan; Daugaard, Soeren; Salat, Christoph; Wendtner, Clemens-Martin; Vujaskovic, Zeljko; Wessalowski, Rüdiger; Jauch, Karl-Walter; Dürr, Hans Roland; Ploner, Ferdinand (June 2010). "Neo-adjuvant chemotherapy alone or with regional hyperthermia for localised high-risk soft-tissue sarcoma: a randomised phase 3 multicentre study". The Lancet. Oncology. 11 (6): 561–570. doi:10.1016/S1470-2045(10)70071-1. ISSN 1474-5488. PMC 3517819. PMID 20434400.
- ^ Issels, Rolf D.; Lindner, Lars H.; Verweij, Jaap; Wessalowski, Rüdiger; Reichardt, Peter; Wust, Peter; Ghadjar, Pirus; Hohenberger, Peter; Angele, Martin; Salat, Christoph; Vujaskovic, Zeljko; Daugaard, Soeren; Mella, Olav; Mansmann, Ulrich; Dürr, Hans Roland (2018-04-01). "Effect of Neoadjuvant Chemotherapy Plus Regional Hyperthermia on Long-term Outcomes Among Patients With Localized High-Risk Soft Tissue Sarcoma: The EORTC 62961-ESHO 95 Randomized Clinical Trial". JAMA Oncology. 4 (4): 483–492. doi:10.1001/jamaoncol.2017.4996. ISSN 2374-2445. PMC 5885262. PMID 29450452.
- ^ "S3-Leitlinie Adulte Weichgewebesarkome" (PDF). AWMF online. Retrieved August 17, 2023.
- ^ Issels, Rolf D.; Noessner, Elfriede; Lindner, Lars H.; Schmidt, Michael; Albertsmeier, Markus; Blay, Jean-Yves; Stutz, Emanuel; Xu, Yujun; Buecklein, Veit; Altendorf-Hofmann, Annelore; Abdel-Rahman, Sultan; Mansmann, Ulrich; von Bergwelt-Baildon, Michael; Knoesel, Thomas (November 2021). "Immune infiltrates in patients with localised high-risk soft tissue sarcoma treated with neoadjuvant chemotherapy without or with regional hyperthermia: A translational research program of the EORTC 62961-ESHO 95 randomised clinical trial". European Journal of Cancer. 158: 123–132. doi:10.1016/j.ejca.2021.09.015. PMID 34666214. S2CID 239035134.
- ^ Multhoff, Gabriele; Botzler, Claus; Wiesnet, Marion; Müller, Eva; Meier, Thomas; Wilmanns, Wolfgang; Issels, Rolf D. (1995-04-10). "A stress-inducible 72-kDa heat-shock protein (HSP72) is expressed on the surface of human tumor cells, but not on normal cells". International Journal of Cancer. 61 (2): 272–279. doi:10.1002/ijc.2910610222. PMID 7705958. S2CID 12228474.
- ^ Noessner, Elfriede; Gastpar, Robert; Milani, Valeria; Brandl, Anna; Hutzler, Peter J. S.; Kuppner, Maria C.; Roos, Miriam; Kremmer, Elisabeth; Asea, Alexzander; Calderwood, Stuart K.; Issels, Rolf D. (2002-11-15). "Tumor-Derived Heat Shock Protein 70 Peptide Complexes Are Cross-Presented by Human Dendritic Cells". The Journal of Immunology. 169 (10): 5424–5432. doi:10.4049/jimmunol.169.10.5424. ISSN 0022-1767. PMID 12421917.
- ^ "Medizinische Klinik und Poliklinik III – Mitarbeiter:innen".
- ^ "Deutscher Krebspreis" (PDF).
- ^ "Reports of Oncological Societies" (PDF). Retrieved August 17, 2023.
- ^ "Past J. Eugene Robinson Award Recipients". Retrieved August 17, 2023.
- ^ "Fellows and Senior Fellows". cellstressresponses.org. Retrieved August 17, 2023.
- ^ "STM Awards". thermaltherapy.org. Retrieved August 17, 2023.